Seven variants were found to associate with the TKI efficacy in a small group of CML patients: rs11579366 (in ANKRD35 gene), rs1990236 (DNAH9), rs176037 (MAGEC1), rs10653661 (TOX3), rs3803264 (THSD1), rs3099950 (MORN2), and rs9471966 (PTCRA). This evidence concerns the gene MAGEC1 and chronic myelogenous leukemia, BCR-ABL1 positive.